利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.018 秒)

    METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES
    2.
    发明授权
    METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES 失效
    用于治疗中枢神经系统涉及的溶酶体贮积病的方法

    公开(公告)号：EP1007043B9

    公开(公告)日：2004-12-22

    申请号：EP98901673.8

    申请日：1998-01-13

    申请人： MONSANTO COMPANY

    发明人： PLATT, Frances, M., University of Oxford ,  NEISES, Gabrielle, R. ,  DWEK, Raymond, A. University of Oxford ,  BUTTERS, Terry D. University of Oxford

    IPC分类号： A61K31/445

    CPC分类号： A61K31/7004 ,  A61K31/445 ,  A61K31/70 ,  A61K31/7012

    摘要： A method is disclosed for the in vivo treatment of patients having a lysosomal storage disease with a significant central nervous system (CNS) involvement. Said method comprises administration to said patient a small but storage-inhibitory effective amount of an N-alkyl derivative of a 1,5-iminosugar in which said alkyl group contains from about 2 to about 8 carbon atoms and said 1,5-iminosugar is 1,5-dideoxy-1,5-imino-D-glucitol, or 1,5-dideoxy-1,5-imino-D-galactitol, or an O-acylated pro-drug of said 1,5-iminosugar. In an illustrative example, CNS storage of GM2 ganglioside is inhibited in Tay-Sachs mice by administration of 1,5-(butylimino)-1,5-dideoxy-D-glucitol.

    摘要翻译： 公开了一种用于体内治疗具有显着中枢神经系统（CNS）参与的溶酶体贮积症患者的方法。 所述方法包括向所述患者施用小但储存抑制有效量的1,5-亚氨基糖的N-烷基衍生物，其中所述烷基含有约2至约8个碳原子且所述1,5-亚氨基糖为 1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇或1,5-二脱氧-1,5-亚氨基-D-半乳糖醇或所述1,5-亚氨基糖的O-酰化前药。 在说明性实例中，通过给予1,5-（丁基亚氨基）-1,5-二脱氧-D-葡萄糖醇在Tay-Sachs小鼠中抑制GM2神经节苷脂的CNS储存。

    PLATELET AGGREGATION INHIBITORS
    5.
    发明授权
    PLATELET AGGREGATION INHIBITORS 失效
    SLIDE聚集抑制剂

    公开(公告)号：EP0804418B1

    公开(公告)日：2003-03-26

    申请号：EP95944838.2

    申请日：1995-12-15

    申请人： G.D. SEARLE & CO.

    发明人： RUMINSKI, Peter, Gerrard

    IPC分类号： C07D213/40 ,  A61K31/44 ,  C07D401/12

    CPC分类号： C07D401/12 ,  C07D213/55

    摘要： This invention herein relates to compounds having formula (I) or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions containing the compound and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.

    Gammasterilisierbares Kulturmedium zum Nachweis von Hefen und Pilzen
    6.
    发明公开
    Gammasterilisierbares Kulturmedium zum Nachweis von Hefen und Pilzen 有权
    一种用于酵母和真菌的选择性探测方法

    公开(公告)号：EP1288290A1

    公开(公告)日：2003-03-05

    申请号：EP02018004.8

    申请日：2002-08-12

    申请人： BIOTEST AG

    发明人： Horn, Jürgen

    IPC分类号： C12N1/14

    CPC分类号： C12N1/14 ,  C12N1/16

    摘要： Gammasterilisierbares Kulturmedium zum selektiven Nachweis von Hefen und Pilzen mit einem Zusatz von Ciprofloxacin und gegebenenfalls Streptomycin oder anderen Antibiotika.

    摘要翻译： 用于选择性检测酵母和真菌的，含有环丙沙星γ射线灭菌的培养基，是新的。

    VERFAHREN ZUR LANGZEITSTABILEN UND GUT REPRODUZIERBAREN SPEKTROMETRISCHEN MESSUNG DER KONZENTRATIONEN DER BESTANDTEILE WÄSSRIGER LÖSUNGEN SOWIE VORRICHTUNG ZUR DURCHFÜHRUNG DIESES VERFAHRENS
    7.
    发明公开
    VERFAHREN ZUR LANGZEITSTABILEN UND GUT REPRODUZIERBAREN SPEKTROMETRISCHEN MESSUNG DER KONZENTRATIONEN DER BESTANDTEILE WÄSSRIGER LÖSUNGEN SOWIE VORRICHTUNG ZUR DURCHFÜHRUNG DIESES VERFAHRENS 审中-公开
    方法长期稳定，重现性好光谱计量配料水溶液的浓度及装置实现它

    公开(公告)号：EP1277039A1

    公开(公告)日：2003-01-22

    申请号：EP01940355.9

    申请日：2001-04-24

    申请人： GlukoMediTech AG

    发明人： ZIRK, Kai-Uwe ,  PÖTZSCHKE, Harald

    IPC分类号： G01N21/31 ,  A61B5/00

    CPC分类号： A61B5/1459 ,  A61B5/14532 ,  G01N21/31

    摘要： The invention relates to a method for the long-term stable and well-reproducible spectrometric measurement of the concentrations of components of aqueous solutions, especially of dialysates of interstitial tissue fluids, especially the glucose concentration. The inventive method comprises splitting a measuring beam into two partial beams by means of a beam splitter (2), and guiding one partial beam through a measuring cuvette (3), that is separated from the solution to be measured for example by a diaphragm, or that is connected to a pump system with an exchange path that is separated from the solution to be measured by a diaphragm. The other partial beam is guided through a reference cuvette (4) that is filled with a reference solution. The light intensity of both partial beams is measured and the measured signals are subjected to a symmetrical signal processing, optionally after suitable amplification. The invention further relates to a device for carrying out the inventive method, which device can be especially miniaturized.

    METHOD OF CELL SURFACE ACTIVATION AND INHIBITION
    8.
    发明授权
    METHOD OF CELL SURFACE ACTIVATION AND INHIBITION 失效
    方法CELL表面活化和抑制

    公开(公告)号：EP0970194B1

    公开(公告)日：2005-04-06

    申请号：EP97903137.4

    申请日：1997-09-15

    申请人： WASHINGTON UNIVERSITY

    发明人： GOLDBERG, Gregory, I. Washington Uni. of Medicine

    IPC分类号： C12N9/64 ,  C12Q1/37 ,  C07K14/81

    CPC分类号： C12N9/6491 ,  C12N9/6489

    摘要： Disclosed are methods of cell surface activation and inhibition that involve the interaction of an inhibitor of matrix metalloprotease known as TIMP-2, with the enzyme, gelatinase-A (GelA). Critical to the methods of the invention is the discovery of a unique TIMP-2 binding site on the surface of the C-terminal domain (GelA-CTD) of the enzyme, which has been determined to be Asp656, but which can also include other residues in the Ge1A-CTD domain with which Asp656 forms a contiguous surface, namely Gly?651, Phe650¿, and Tyr636. Identification of this binding site provides a useful target for the screening of MMP inhibitors and for prognosis and treatment of diseases in which MMPs are implicated. Compounds which are candidate MMP inhibitors can be structured to competitively inhibit cell surface activation.